[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413541":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":41,"collaborators":20,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":20,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":20,"enrollmentInfo":54,"targetDuration":20,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":20,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intra-arterial administration of 3-n-butylphthalide","EXPERIMENTAL","Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug\u002Fmin.",[13],"Drug: Intra-arterial administration of neuroprotective agents",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Intra-arterial administration of neuroprotective agents","Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug\u002Fmin",[9],null,[22],{"facility":23,"status":24,"city":25,"state":20,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Department of Neurology, General Hospital of Northern Theater Command","RECRUITING","Shenyang","110016","China","CN",{"type":30,"coordinates":31},"Point",[32,33],123.43278,41.79222,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"Hui-Sheng Chen, Ph.D.","CONTACT","+86 13352452086","chszh@aliyun.com",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Hui-Sheng Chen","Director","100413541","intra-arterial-neuroprotective-strategy-for-ischemic-stroke-patients-with-endovascular-therapy-insist-et-100413541",false,"NCT04664933","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Acute ischemic stroke patients who is eligible for endovascular treatment;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\\\u003C80000\u002Fmm3);\n3. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n4. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n5. Unsuitable for this clinical studies assessed by researcher.","ALL","18 Years",{"count":55,"type":56},30,"ESTIMATED","INTERVENTIONAL",[59],"NA","To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.",[62,63,64],"Stroke, Ischemic","Intravascular Thrombosis","Mechanical Thrombectomy","2025-08-20",{"date":67,"type":68},"2025-08-21","ACTUAL",{"date":70,"type":68},"2020-12-01",{"date":72,"type":56},"2026-05-31",{"name":43,"class":6},1]